Reported 3 months ago
Merck & Co reported strong second-quarter results, driven by significant sales of its cancer drug Keytruda, which reached $7.3 billion, up 16% from the previous year. The company posted a profit of $5.5 billion, beating analyst estimates and slightly raised its annual sales forecast to between $63.4 billion and $64.4 billion. However, it adjusted its earnings outlook downward due to costs associated with acquisitions.
Source: YAHOO